3月10日 - ** 制药商Emergent BioSolutions EBS.N股价下跌3%至5.60美元，创九个月新低
** 印度新基因国际公司SYNN.NS称， (link)，该公司以3650万美元的价格从Emergent Manufacturing Operations Baltimore公司（EBS的子公司）手中收购了其在美国的第一家生物制剂工厂。
** 预计交易将于 2025 年 3 月完成
** 公司表示，该工厂预计将于 2025 年下半年开始为客户项目提供服务
** 截至上次交易结束，EBS 在过去 12 个月中的股价上涨了一倍多。
(为便利非英文母语者，路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.